Characterization of placenta-derived mesenchymal stem cells cultured in autologous human cord blood serum

Wang,Libin; Yang,Yinxue; Zhu,Yongzhao; Ma,Xiaona; Liu,Ting; Zhang,Guangyi; Fan,Heng; Ma,Lijun; Jin,Yiran; Yan,Xiurui; Wei, Jun; Li,Yukui

doi:10.3892/mmr.2012.1000

Characterization of placenta-derived mesenchymal stem cells cultured in autologous human cord blood serum

Authors:
- Libin Wang
- Yinxue Yang
- Yongzhao Zhu
- Xiaona Ma
- Ting Liu
- Guangyi Zhang
- Heng Fan
- Lijun Ma
- Yiran Jin
- Xiurui Yan
- Jun Wei
- Yukui Li
View Affiliations

Affiliations: Ningxia Human Stem Cell Institute, The Affiliated Hospital of Ningxia Medical University, Yinchuan, Ningxia, P.R. China, Key Laboratory of Fertility Preservation and Maintenance of Ningxia Medical University, Yinchuan, Ningxia, P.R. China
Published online on: July 23, 2012 https://doi.org/10.3892/mmr.2012.1000
Pages: 760-766

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human placenta-derived mesenchymal stem cells (P-MSCs) have drawn increasing attention in the field of stem cell research due to their potential in clinical applications as well as their rich and easy to procure cell source. While studies demonstrating the potential of P-MSCs for therapeutic transplantations have been documented, a clinically compliant procedure for P-MSC expansion in vitro has yet to be established. To this end, previous studies have demonstrated that MSCs of bone marrow and cord blood origins cultured in human cord blood serum (hCBS) are comparable to those cultured in fetal bovine serum (FBS), indicating that hCBS may be an alternative to FBS for the development of in vitro cell expansion procedures free of animal components. However, stem cells from origins other than bone marrow or cord blood, particularly from human placental tissues, which have demonstrated a good potential for clinical applications, have not been characterized under similar conditions. In this study, in an attempt to define a clinically compliant protocol for P-MSC expansion in vitro, we examined the effects of human hCBS as a replacement for FBS on cell proliferation capacity, differentiation potential, MSC-specific phenotypic expression and the genetic stability of P-MSCs in cultures. P-MSCs expanded in vitro in autologous hCBS maintained the capacity of self‑renewal and expressed surface antigens characteristic of bone marrow-derived mesenchymal stem cells. Under differentiation conditions, the P-MSCs expanded in hCBS developed into adipogenic, osteogenic and neurogenic cell phenotypes. Chromosomal karyotyping and single cell gel electrophoresis analysis demonstrated that P-MSCs cultured in autologous hCBS were genetically stable. These results suggest that autologous hCBS may be used as an alternative to FBS for the in vitro expansion of P-MSCs for clinical applications.

View Figures

View References

1	Brooke G, Cook M, Blair C, et al: Therapeutic applications of mesenchymal stromal cells. Semi Cell Dev Biol. 18:846–858. 2007. View Article : Google Scholar : PubMed/NCBI
2	Le Blanc K, Frassoni F, Ball L, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 371:1579–1586. 2008.
3	Sun LY, Kentaro A, Zhang HY, et al: Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 27:1421–1432. 2009. View Article : Google Scholar : PubMed/NCBI
4	Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M and Karli D: Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 11:343–353. 2008.
5	Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG and Prockop DJ: Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells. 20:530–541. 2002. View Article : Google Scholar : PubMed/NCBI
6	Parolini O, Alviano F, Bergwerf I, et al: Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev. 19:143–155. 2010. View Article : Google Scholar
7	Chang CJ, Yen ML, Chen YC, et al: Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 24:2466–2477. 2006. View Article : Google Scholar
8	Magatti M, De Munari S, Vertua E, Gibelli L, Wengler GS and Parolini O: Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells. 26:182–192. 2008. View Article : Google Scholar : PubMed/NCBI
9	Bailo M, Soncini M, Vertua E, et al: Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation. 78:1439–1448. 2004. View Article : Google Scholar : PubMed/NCBI
10	Li H, Niederkorn JY, Neelam S, et al: Immunosuppressive factors secreted by human amniotic epithelial cells. Invest Ophthalmol Vis Sci. 46:900–907. 2005. View Article : Google Scholar : PubMed/NCBI
11	Magatti M, De Munari S, Vertua E, et al: Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant. 18:899–914. 2009. View Article : Google Scholar : PubMed/NCBI
12	Pittenger MF, Mackay AM, Beck SC, et al: Multilineage potential of mesenchymal cells. Science. 284:143–147. 1999. View Article : Google Scholar
13	Mareschi K, Ferrero I, Rustichelli D, et al: Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem. 97:744–754. 2006. View Article : Google Scholar : PubMed/NCBI
14	Evangelista M, Soncini M and Parolini O: Placenta-derived stem cells: new hope for cell therapy. Cytotechnology. 58:33–42. 2008. View Article : Google Scholar : PubMed/NCBI
15	Barlow S, Brooke G, Chatterjee K, et al: Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev. 17:1095–1107. 2008. View Article : Google Scholar : PubMed/NCBI
16	Portmann-Lanz CB, Schoeberlein A, Huber A, et al: Placental mesenchymal stem cells as potential autologous graft for preand perinatal neuroregeneration. Am J Obstet Gynecol. 194:664–673. 2006. View Article : Google Scholar : PubMed/NCBI
17	Sakuragawa N, Kakinuma K, Kikuchi A, et al: Human amnion mesenchyme cells express phenotypes of neuroglial progenitor cells. J Neurosci Res. 78:208–214. 2004. View Article : Google Scholar : PubMed/NCBI
18	Wei JP, Zhang TS, Kawa S, et al: Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice. Cell Transplant. 12:545–552. 2003. View Article : Google Scholar : PubMed/NCBI
19	Roelen DL, van der Mast BJ, in’t Anker PS, et al: Differential immunomodulatory effects of fetal versus maternal multipotent stromal cells. Hum Immunol. 70:16–23. 2009. View Article : Google Scholar : PubMed/NCBI
20	Brooke G, Rossetti T, Pelekanos R, et al: Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol. 144:571–579. 2008. View Article : Google Scholar : PubMed/NCBI
21	Mannello F and Tonti GA: No breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? all that glitters is not gold! Stem Cells. 25:1603–1609. 2007.
22	Tuschong L, Soenen SL, Blaese RM, Candotti F and Muul LM: Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther. 13:1605–1610. 2002. View Article : Google Scholar : PubMed/NCBI
23	Spees JL, Gregory CA, Singh H, et al: Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther. 9:747–756. 2004. View Article : Google Scholar : PubMed/NCBI
24	Berger MG, Veyrat-Masson R, Rapatel C, Descamps S, Chassagne J and Boiret-Dupre N: Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells. 24:2888–2990. 2006. View Article : Google Scholar : PubMed/NCBI
25	Lam AC, Li K, Zang ZB, et al: Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice. Transfusion. 41:1567–1576. 2001. View Article : Google Scholar : PubMed/NCBI
26	Kim YM, Jung MH, Song HY, et al: Ex vivo expansion of Human umbilical cord blood derived T lymphocytes with homologous cord blood plasma. Tohoku J Exp Med. 205:115–122. 2005. View Article : Google Scholar : PubMed/NCBI
27	Shetty P, Bharucha K and Tanavde V: Human umbilical cord blood serum can replace fetal bovine serum in the culture of mesenchymal stem cells. Cell Biol Int. 31:293–298. 2007. View Article : Google Scholar : PubMed/NCBI
28	Mizuno N, Shiba H, Ozeki Y, et al: Human autologous serum obtained using a completely closed bag system as a substitute for foetal calf serum in human mesenchymal stem cell cultures. Cell Biol Int. 30:521–524. 2006. View Article : Google Scholar : PubMed/NCBI
29	Xia SX, Gao YZ, Bian SZ, et al: Genetic polymorphisms of two STR loci D2S1399 and D5S2500 in eastern Chinese Han population. Fa Yi Xue Za Zhi. 20:200–201. 2004.PubMed/NCBI
30	Nievas P, Martinez Jarreta B, Abecia E and Lareu MV: Fluorescence based amplification of the STR loci D18S535, D1S1656 and D12S391 in a population sample from Aragon (North Spain). Int J Legal Med. 113:58–59. 1999. View Article : Google Scholar : PubMed/NCBI
31	Parolini O, Alviano F, Bagnara GP, et al: Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells. 26:300–311. 2008. View Article : Google Scholar : PubMed/NCBI
32	Caplan AL: Why are MSCs therapeutic? New data: new insight. J Pathol. 217:318–324. 2009. View Article : Google Scholar : PubMed/NCBI
33	Fazekasova H, Lechler R, Langford K and Lombardi G: Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs. J Tissue Eng Regen Med. 5:684–694. 2011. View Article : Google Scholar : PubMed/NCBI
34	Pilz GA, Ulrich C, Ruh M, et al: Human term placenta-derived mesenchymal stromal cells are less prone to osteogenic differentiation than bone marrow-derived mesenchymal stromal cells. Stem Cells Dev. 20:635–646. 2011. View Article : Google Scholar : PubMed/NCBI
35	Mohr S, Portmann-Lanz CB, Schoeberlein A, Sager R and Surbek DV: Generation of an osteogenic graft from human placenta and placenta-derived mesenchymal stem cells. Reprod Sci. 17:1006–1015. 2010. View Article : Google Scholar : PubMed/NCBI